Analyst Sarita Kapila of Morgan Stanley maintained a Hold rating on Roche Holding AG, retaining the price target of CHF286.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sarita Kapila has given her Hold rating due to a combination of factors influencing Roche Holding AG’s financial performance. The company’s Q2 and H1 2025 results showed a slight outperformance against market expectations, with a 1% sales beat primarily driven by the Pharmaceuticals division, which exceeded expectations by 2%. However, this was somewhat counterbalanced by a 4% miss in the Diagnostics division, highlighting some underlying challenges.
Despite the overall positive financial results, including a 5% beat in core EPS due to a lower tax rate, the outlook remains cautious. Roche reiterated its FY’25 guidance, projecting moderate sales growth and high single-digit EPS growth, but with anticipated currency impacts potentially affecting these figures. The upcoming launch of biosimilars in the US by the end of 2026 and the delay in Phase 3 data for fenebrutinib also contribute to a conservative stance, justifying the Hold rating as the company navigates these mixed signals and external pressures.
Kapila covers the Healthcare sector, focusing on stocks such as Roche Holding AG, GlaxoSmithKline, and Sanofi. According to TipRanks, Kapila has an average return of -1.0% and a 53.85% success rate on recommended stocks.
In another report released today, Jefferies also maintained a Hold rating on the stock with a CHF270.00 price target.